The estimated Net Worth of Joel Lewis is at least $607 Mille dollars as of 24 April 2024. Mr Lewis owns over 1,000 units of Galectin Therapeutics Inc stock worth over $5,480 and over the last 7 years he sold GALT stock worth over $0. In addition, he makes $601,098 as Pres e CEO & Director at Galectin Therapeutics Inc.
Sign up
Mr Lewis GALT stock SEC Form 4 insiders trading
Mr has made over 8 trades of the Galectin Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of GALT stock worth $3,390 on 24 April 2024.
The largest trade he's ever made was buying 12,849 units of Galectin Therapeutics Inc stock on 31 May 2019 worth over $54,994. On average, Mr trades about 268 units every 22 days since 2017. As of 24 April 2024 he still owns at least 2,000 units of Galectin Therapeutics Inc stock.
You can see the complete history of Mr Lewis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Joel Lewis biography
Joel Lewis is the Pres, CEO & Director at Galectin Therapeutics Inc.
What is the salary of Mr Lewis?
As the Pres e CEO & Director of Galectin Therapeutics Inc, the total compensation of Mr Lewis at Galectin Therapeutics Inc is $601,098. There are 4 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.
How old is Mr Lewis?
Mr Lewis is 51, he's been the Pres e CEO & Director of Galectin Therapeutics Inc since . There are 14 older and 5 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.
What's Mr Lewis's mailing address?
Joel's mailing address filed with the SEC is 4960 Peachtree Industrial Blvd #240, Norcross, GA 30071, USA.
Insiders trading at Galectin Therapeutics Inc
Over the last 13 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr e Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
What does Galectin Therapeutics Inc do?
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
What does Galectin Therapeutics Inc's logo look like?
Complete history of Mr Lewis stock trades at Galectin Therapeutics Inc
Galectin Therapeutics Inc executives and stock owners
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Harold Shlevin,
Director -
Jack Callicutt,
Chief Financial Officer, Secretary -
Dr. Pol F. Boudes M.D., Ph.D.,
Chief Medical Officer -
Dr. Pol F. Boudes,
Chief Medical Officer -
Joel Lewis,
Pres, CEO & Director -
Kevin Freeman,
Independent Director -
Joel Lewis,
President, Chief Executive Officer, Director -
Richard Uihlein,
Independent Chairman of the Board -
Gilbert Amelio,
Independent Director -
Gilbert Omenn,
Independent Director -
Kary Eldred,
Independent Director -
Eliezer Zomer,
Executive Vice President - Manufacturing and Product Development -
Marc Rubin,
Independent Director -
James Czirr,
Director -
Richard Zordani,
Independent Director -
Elissa Schwartz,
Independent Director -
Pol Boudes,
Chief Medical Officer -
J. Rex Horton,
Executive Director - Regulatory Affairs and Quality Assurance -
Adam Allgood,
Executive Director of Clinical Development -
Beth Knowles,
Exec. Assistant & Officer Mang. -
Robert Tritt,
Gen. Counsel -
Jack W. Callicutt CPA, CPA,
CFO, Treasurer & Sec. -
Theodore Daniel Zucconi,
Director -
John F Mauldin,
Director -
Fund, L.P.10 X Capital Mana...,
-
Steven Prelack,
Director -
Arthur Greenberg,
Director -
Khurram Jamil,
Chief Medical Officer -
Benjamin Sr Carson,
-
Stephen Shulman,
Director -
Fund, L.P.10 X Capital Mana...,
-
Peter G Traber,
CEO and President -
Herman Paul Pressler,
Director -
Thomas Mcgauley,
Chief Financial Officer -
Rod D Martin,
Director -
Jerald K Rome,
Director -
Fund, L.P.Czirr James C10 X...,